Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 19/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777031 | 0.81 | NOTUM (1.00) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL30413222 | 0.79 | NOTUM (0.65) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL30413718 | 0.79 | NOTUM (0.65) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL19814171 | 0.76 | NOTUM (0.61) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL9911397 | 0.76 | NOTUM (0.61) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL21776828 | 0.75 | NOTUM (1.00) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL19823735 | 0.73 | NOTUM (0.57) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL19823245 | 0.73 | NOTUM (0.57) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL29842592 | 0.73 | NOTUM (0.59) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL27531505 | 0.73 | NOTUM (0.59) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885CYP1A2 2434/4885CYP2C9 4595/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885CYP1A2 1415/4885CYP2C9 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.